ArticleHaematologica2012
Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial.
Article in Haematologica, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed.
- A Phase II, Open-Label Study of Lenalidomide and Dexamethasone Followed by Donor Lymphocyte Infusions in Relapsed Multiple Myeloma Following Upfront Allogeneic Stem Cell Transplant.Current oncology (Toronto, Ont.) · 2024Trial
- Impact of Novel Agents on Allogeneic Hematopoietic Cell Transplantation in Patients with T-Cell Lymphomas.Cells · 2025Review
- Maintenance strategies for relapse prevention and treatment.Hematology. American Society of Hematology. Education Program · 2024Review
- Human amniotic epithelial stem cell is a cell therapy candidate for preventing acute graft-versus-host disease.Acta pharmacologica Sinica · 2024Article
- A phase 1 dose-escalation study of low-dose lenalidomide maintenance post-allogeneic stem cell transplantation for high-risk acute myeloid leukaemia or myelodysplastic syndrome.Bone marrow transplantation · 2024Article
- Article
- Novel Approaches to Treatment of Acute Myeloid Leukemia Relapse Post Allogeneic Stem Cell Transplantation.International journal of molecular sciences · 2023Review
- Lenalidomide with or without dexamethasone for relapsed or refractory Hodgkin lymphoma post autologous stem cell transplant.Blood cell therapy · 2023Article
- Azacitidine and lenalidomide combination: a novel relapse prophylaxis regimen after allogeneic hematopoietic stem-cell transplantation in patients with acute myeloid leukemia.Frontiers in immunology · 2023Article
- Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies.Blood advances · 2022Article
- Early administration of lenalidomide after allogeneic hematopoietic stem cell transplantation suppresses graft-versus-host disease by inhibiting T-cell migration to the gastrointestinal tract.Immunity, inflammation and disease · 2022Article
- Maintenance therapy for AML after allogeneic HCT.Frontiers in oncology · 2022Review
- The prevention of disease relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia.Frontiers in oncology · 2022Review
- Generalist in allogeneic hematopoietic stem cell transplantation for MDS or AML: Epigenetic therapy.Frontiers in immunology · 2022Review
- Lenalidomide as a Potent Inducer of Graft Versus Leukemia Effect in Patients with Hematologic Malignancies at High Risk of Relapse Post Allogeneic Stem Cell Transplant.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2021Article
- Therapeutic Use of Valproic Acid and All-Trans Retinoic Acid in Acute Myeloid Leukemia-Literature Review and Discussion of Possible Use in Relapse after Allogeneic Stem Cell Transplantation.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Biology of Disease Relapse in Myeloid Disease: Implication for Strategies to Prevent and Treat Disease Relapse After Stem-Cell Transplantation.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Review
- Optimizing Transplant Approaches and Post-Transplant Strategies for Patients With Acute Myeloid Leukemia.Frontiers in oncology · 2021Review
- Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: Who, When, and How?Frontiers in immunology · 2021Review
- Hypomethylating Agent-Based Combination Therapies to Treat Post-Hematopoietic Stem Cell Transplant Relapse of Acute Myeloid Leukemia.Frontiers in oncology · 2021Review
Corrections and comments
- Comment on
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.